Latest news for Newtopia (OTC:NEWUF) Stock

Newtopia Inc is a technology-enabled habit change company that delivers disease prevention solutions by leveraging genetic testing, and social and behavioral science to help individuals prevent chronic disease and reduce costs for health insurers.

News

Penny Stocks

Health Care

Markets

General

NEWUF

TSXV:NEWU

Focusing on Disease Prevention Can Benefit Individuals and Health Insurers - A New Approach to Healthcare

Newtopia Inc

JP Morgan analyst Ryan Brinkman maintains Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) with a Neutral and lowers the price target from $36 to $35.

Price Target

Analyst Ratings

GNTX

JP Morgan Maintains Neutral on Gentex, Lowers Price Target to $35

RBC Capital analyst Scott Heleniak maintains Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) with a Sector Perform and lowers the price target from $103 to $96.

SIGI

SLBRBC Capital Maintains Sector Perform on Selective Insurance Gr, Lowers Price Target to $96

Politics

Evercore Founder Roger Altman Endorses Kamala Harris

MIRA Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>)&nbsp;announced new preclinical study results for its novel oral ketamine analog, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/ac39880944/mira-pharmaceuticals-reveals-preclinical-success-ketamir-2-optimized-for-brain-delivery-avoiding-" rel="noreferrer noopener">Ketamir-2</a>.
MIRA Pharmaceuticals is developing the next generation of oral ketamine and pharmaceutical marijuana analogs to treat <a target="_blank" href="https://www.benzinga.com/news/24/07/39777820/why-mira-pharmaceuticals-stock-is-moving-higher-monday" rel="noreferrer noopener">neurologic neuropsychiatric disorders</a>.&nbsp;
The additional data comes as MIRA prepares to submit an Investigational New Drug (IND) application to the FDA by the end of this year.
Ketamir-2 is under investigation for its potential to treat neurological and neuropsychiatric disorders, including depression, treatment-resistant depression, and post-traumatic stress disorder.
Ketamir-2 has demonstrated in&nbsp;in vitro&nbsp;studies that it is not a substrate for interaction with P-glycoprotein (P-gp). This membrane protein typically pumps many drugs out of cells, including cells in the brain.
This characteristic might allow Ketamir-2 to have better oral absorption and to penetrate the blood-brain barrier more effectively than traditional ketamine, which is a substrate of P-gp.
MIRA&#8217;s preclinical research indicates that Ketamir-2 exhibits better oral bioavailability, which could ensure higher efficacy at lower doses than traditional ketamine.
MIRA previously announced that Ketamir-2&#8217;s oral bioavailability is predicted to be around 80%, significantly higher than traditional ketamine&#8217;s less than 30%.
Additionally, preclinical studies have shown that while oral Ketamir-2 has been shown to be safe at high doses and is effective in several anti-depressant and anxiolytic models, and it does not appear to induce hyper-locomotor activity, a common side effect of traditional ketamine.
Moreover, Ketamir-2 has shown no interaction with the mu-opioid receptor, unlike traditional ketamine. This could potentially mean a reduced risk of opioid-related side effects and dependency.
Recent studies further highlight Ketamir-2&#8217;s anti-depressive and anxiolytic effects in a mouse model, with significant improvements in behavioral tests compared to traditional ketamine.
MIRA has additional ongoing preclinical studies to demonstrate Ketamir-2&#8217;s potential efficacy in treating chemotherapy-induced depression and cancer-related neuropathic pain. The company is exploring options for orphan drug indications such as multiple sclerosis-induced depression and Huntington&#8217;s disease-induced depression.
Price Action: MIRA stock is up 151.20% at $1.73 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39864990/cell-therapy-mostly-used-for-blood-cancer-shows-efficacy-in-autoimmune-diseases-as-well-but-there" target="_blank" rel="noreferrer noopener">Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges</a>.</li>
</ul>
Image via Shutterstock

Movers

MIRA

Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders

JP Morgan analyst Ryan Brinkman maintains Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) with a Overweight and lowers the price target from $18 to $17.

JP Morgan Maintains Overweight on Dana, Lowers Price Target to $17

Fortinet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NYSE">FTNT</a>) short percent of float has risen 12.83% since its last report. The company recently reported that it has 16.06 million shares sold short, which is 2.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fortinet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721658622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fortinet has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Fortinet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fortinet's peer group average for short interest as a percentage of float is 5.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

FTNT

(FTNT) - Analyzing Fortinet's Short Interest

Warrior Met Coal's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCC#NYSE">HCC</a>) short percent of float has risen 44.2% since its last report. The company recently reported that it has 3.98 million shares sold short, which is 10.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Warrior Met Coal Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721658616_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Warrior Met Coal has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Warrior Met Coal's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Warrior Met Coal's peer group average for short interest as a percentage of float is 5.80%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(HCC) - Analyzing Warrior Met Coal's Short Interest

GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) has outperformed the market over the past 20 years by 5.26% on an annualized basis producing an average annual return of 13.63%. Currently, GameStop has a market capitalization of $10.57 billion. 
Buying $1000 In GME: If an investor had bought $1000 of GME stock 20 years ago, it would be worth $13,122.44 today based on a price of $24.79 for GME at the time of writing.
<h3>GameStop's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721658616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $13,000 Today

Oppenheimer analyst Kristen Owen maintains Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) with a Outperform and lowers the price target from $28 to $21.

GPRE

Oppenheimer Maintains Outperform on Green Plains, Lowers Price Target to $21

Howmet Aerospace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) short percent of float has risen 16.29% since its last report. The company recently reported that it has 11.04 million shares sold short, which is 3.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Howmet Aerospace Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721658612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Howmet Aerospace has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Howmet Aerospace's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Howmet Aerospace's peer group average for short interest as a percentage of float is 2.43%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Howmet Aerospace's Recent Short Interest

Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) has outperformed the market over the past 5 years by 4.87% on an annualized basis producing an average annual return of 17.71%. Currently, Tyler Technologies has a market capitalization of $22.26 billion. 
Buying $100 In TYL: If an investor had bought $100 of TYL stock 5 years ago, it would be worth $229.71 today based on a price of $524.33 for TYL at the time of writing.
<h3>Tyler Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721658611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Tyler Technologies Stock In The Last 5 Years

JP Morgan analyst Ryan Brinkman maintains BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) with a Overweight and lowers the price target from $52 to $50.

JP Morgan Maintains Overweight on BorgWarner, Lowers Price Target to $50

WIIM

CABO

CHTR

CMCSA

Shares of telecom stocks are trading lower in sympathy with Verizon Communications after the company reported worse-than-expected Q2 revenue results.

Oppenheimer analyst Kristen Owen maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Outperform and lowers the price target from $465 to $448.

Oppenheimer Maintains Outperform on Deere, Lowers Price Target to $448

Shares of Lennar Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) declined in premarket trading on Monday, just weeks after the company announced plans to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39693554/why-this-lennar-analyst-is-no-longer-bearish-after-6b-spinoff-plan">spin off its land assets</a>.
Although the company is poised to benefit from its greater exposure to entry level and first-time buyers as the Federal Reserve cuts interest rates, this is already reflected in the stock valuation, according to Goldman Sachs.
The Lennar Analyst: Susan Maklari downgraded the rating for Lennar from Buy to Neutral, while reducing the price target from $180 to $174.
The Lennar Thesis: Following the recent outperformance, the stock may remain range bound in the near term, Maklari said in the downgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Lennar's exposure to entry level is likely to result in margin expansion, the analyst stated. She explained that Lennar is focusing on adding affordable supply to the market, targeting first-time buyers, and shifting to a manufacturing-based strategy, which boosts efficiency.
"As rates move lower, easing financial incentives, we believe profitability could expand, supporting earnings and greater cash generation," Maklari wrote.
Lennar's proposed spinoff of owned land for $6 billion to $8 billion "could drive a re-rating of LEN over time, as the market assesses the company's new profile if and when the spin is completed, as well as decisions around capital allocation, notably shareholder returns," she added.
LEN Price Action: Shares of Lennar had declined by 1.5% to $168.39 at last check on Monday.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39879895/if-youre-a-lawyer-for-crowdstrike-youre-probably-not-going-to-enjoy-the-rest-of-your-summer-say-dan">&#8216;If You&#8217;re A Lawyer For Crowdstrike, You&#8217;re Probably Not Going To Enjoy The Rest Of Your Summer&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Downgrades

Why This Lennar Analyst Is No Longer Bullish Despite Potential Rate Cut Benefits

RBC Capital Maintains Sector Perform on Selective Insurance Gr, Lowers Price Target to $96

JP Morgan analyst Ryan Brinkman maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Overweight and lowers the price target from $113 to $104.

APTV

JP Morgan Maintains Overweight on Aptiv, Lowers Price Target to $104

President Joe Biden has announced that<a href="https://twitter.com/JoeBiden/status/1815080881981190320"> he will not seek reelection in 2024</a>. In a letter posted on his official X account, Biden expressed his belief that stepping down is in the best interest of his party and the country.
&#8220;It has been the greatest honor of my life to serve as your President&#8230; I believe it is in the best interest of my party and the country for me to stand down,&#8221; he wrote. Biden has <a href="https://twitter.com/JoeBiden/status/1815087772216303933">endorsed Vice </a><a href="https://twitter.com/JoeBiden/status/1815087772216303933">President Kamala Harris</a> for the Democratic presidential nomination, leading to potential shifts in the political landscape and regulatory environment.
<h3 class="wp-block-heading">Impact on VanEck&#8217;s Solana ETF Proposal</h3>
So, what does this mean for the future of cryptocurrency? Matthew Sigel, head of digital assets research at VanEck, recently confirmed that the firm's proposal for a Solana spot ETF is <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39598039/vanecks-solana-etf-proposal-dependent-on-trumps-presidential-win-matthew-sigel-confirms">contingent on the outcome of the 2024 presidential elections</a>. The application deadline for the ETF is set for March 2025. Sigel stated, &#8220;Can confirm,&#8221; indicating the importance of the election results for the proposal&#8217;s success.
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/21145238/905735A6-57D3-4874-9AA1-75D037842DB3-1-13.gif" alt="" class="wp-image-447438" style="width:322px;height:auto" /></a></figure>
Analysts suggest that the ETF&#8217;s approval chances would increase if a Republican administration, like former president Donald Trump, replaced the current leadership, potentially appointing a new SEC chair. Current SEC Chair Gary Gensler has been critical of various crypto regulations, which has drawn significant attention from the industry.
<h3 class="wp-block-heading">Regulatory Challenges and Market Reactions</h3>
The likelihood of VanEck's Solana ETF approval is closely tied to potential changes in SEC leadership. Gensler has been vocal against parts of the FIT21 Crypto Bill, which he believes could create regulatory gaps. This stance has faced criticism from the crypto community, including from <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38814794/billionaire-shark-mark-cuban-warns-the-secs-anti-crypto-stance-could-cost-biden-the-electi">renowned investor Mark Cuban</a>. The regulatory environment remains a critical factor in the approval process for such ETFs.
Following VanEck's ETF filing, <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39528468/vaneck-files-solana-etf-application-sol-rallies-6">Solana's price surged by 6%</a>. The asset has seen a significant increase in value, outpacing both Bitcoin and Ethereum over a recent seven-day period. Another firm, 21Shares, also announced a<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39555344/21shares-becomes-the-next-fund-filing-for-a-solana-spot-etf"> similar ETF application</a>, further contributing to the upward trend in Solana's price.
<h3 class="wp-block-heading">Benzinga's Future of Digital Assets Event in Focus</h3>
These developments will be a major point of discussion at <a href="https://www.benzinga.com/events/digital-assets/">Benzinga's Future of Digital Assets </a>event in November, which will occur after the election results. The event, set to take place in New York City, will gather digital asset innovators and industry leaders to explore the future of money. 
With over 1,000 capital markets leaders expected to attend, the event promises extensive networking opportunities and in-depth discussions on the evolution of alternative assets.
President Biden&#8217;s decision not to run for reelection and his endorsement of Harris introduce new dynamics in the regulatory outlook for cryptocurrency ETFs. As the industry anticipates potential shifts in SEC leadership, the upcoming Benzinga's Future of Digital Assets event will offer valuable opportunities to understand and navigate these changes. The event will be crucial for those looking to stay informed and connected in the rapidly evolving digital assets space.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39884149/michelle-obama-for-democratic-nominee-crypto-bettors-think-her-odds-have-just-tripled">Michelle Obama For Democratic Nominee? Crypto Bettors Think Her Odds Have Just Tripled</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Biden Withdraws From 2024 Race: What That Means For Solana ETF Prospects

President Joe Biden's announcement not to seek reelection has caused ripple effects in betting markets and <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39866311/biden-inspired-boden-meme-coin-keeps-plummeting-but-harris-newsom-coins-surge-on-nominee-s">PoliFi meme coins.</a>
What Happened: Polymarket trader &#8216;AnonBidenBull&#8217; lost $2 million betting on the President to become the Democratic nominee for the 2024 election, winning the Presidential election and the popular vote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#39;AnonBidenBull&#39; just lost $2,000,000. <a href="https://t.co/MGAoUKOx0K">pic.twitter.com/MGAoUKOx0K</a>
&mdash; Polymarket (@Polymarket) <a href="https://twitter.com/Polymarket/status/1815115526043017727?ref_src=twsrc%5Etfw">July 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On the other hand, popular Polymarket trader &#8216;Domer&#8217; <a href="https://x.com/Domahhhh/status/1815089259449344193">reported</a> a profit of around $800,000 on betting Joe Biden to drop out of the race.
Yet another <a href="https://x.com/Polymarket/status/1815121331773440393">trader</a> wagered $12,500 on Kamala Harris to become the 2024 Democratic nominee, seeing their position&#8217;s value skyrocket by over 6,000% to nearly $769,000. Polymarket currently estimates Harris&#8217; odds at 79%.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39880291/president-bidens-exit-followed-nearly-80m-in-wagers-on-crypto-prediction-market-polymarket">President Biden&#8217;s Exit Followed Nearly $80M In Wagers On Crypto Prediction Market Polymarket</a>
Why It Matters: These incidents underscore the inherent risks associated with prediction markets like Polymarket, where outcomes are highly dependent on unpredictable political events. The recent surge in activity on Polymarket, particularly from crypto traders, indicates a growing interest in these markets, despite the risks.
Crypto trader Toby <a href="https://x.com/clippedtoby/status/1815090179666788481">tweeted</a> the story of a trader who switched his $8 million investment from Jupiter (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">JUP</a>) to Biden-themed meme coin Jeo Boden (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BODEN</a>) at the latter's peak. Later he sold $12,500 worth of shares but held on to the rest. Currently, he is down 98% on the bet, turning the initial $8 million into $85,000. "Rich people can also be incredibly stupid," the trader commented on the example.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Reminder: Rich people can also be incredibly stupid. This trader TWAP&#39;d out of $8m worth of <a href="https://twitter.com/search?q=%24JUP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$JUP</a> for <a href="https://twitter.com/search?q=%24BODEN&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BODEN</a> at the pico top of Boden. He then sold $12.5k worth (0.5% of total) but bagheld the rest to now, where he is down near to 98%. His $8m is now worth about $85k at… <a href="https://t.co/w4jAvInuBB">pic.twitter.com/w4jAvInuBB</a>
&mdash; toby (@clippedtoby) <a href="https://twitter.com/clippedtoby/status/1815090179666788481?ref_src=twsrc%5Etfw">July 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another trader <a href="https://x.com/trading_vapor/status/1815355930881425530">highlighted</a> this downtrend as "the very reason why you don&#8217;t want to hold memes that are too specific or tied to a particular." He suggested that unique and universal memes are a better option.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a style="font-weight: bold;" href="https://www.benzinga.com/markets/cryptocurrency/24/07/39875286/bidens-odds-of-finishing-term-drop-sharply-on-crypto-prediction-market-coin-themed-after-p">Biden&#8217;s Odds Of Finishing Term Drop Sharply On Crypto Prediction Market, Coin Themed After President Bleeds 60%</a></li>
</ul>
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image created using artificial intelligence with Midjourney.

$BODEN

$JUP

Meet The Traders Who Lost $2M And $8M Betting On Biden And The 'Jeo Boden' Meme Coin

Oppenheimer analyst Jed Kelly maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Outperform and raises the price target from $4200 to $4600.

BKNG

Oppenheimer Maintains Outperform on Booking Holdings, Raises Price Target to $4600

Newtopia&nbsp; reports Q2 results

Newtopia reports Q3 results

Newtopia GAAP EPS of -C$0.01, revenue of C$1.81M

Small Cap

Press Releases

Newtopia and Arvest Bank Partner to Prevent, Slow and Reverse Chronic Disease Through Sustainable Habit Change

Arvest Bank, Newtopia Partner to Prevent, Slow, and Reverse Chronic Disease Through Sustainable Habit Change

Contracts

Newtopia Engages ICP Securities Inc. for Automated Market Making Services

Earnings

Newtopia Announces Delay in Annual Filings

Newtopia Schedules Combined Fourth Quarter 2023 and First Quarter 2024 Earnings Release and Conference Call

Newtopia Reports Fourth Quarter, Full Year 2023 and First Quarter 2024 Financial Results

NEWTOPIA CONFIRMS STRATEGIC ALTERNATIVE REVIEW PROCESS TO MAXIMIZE SHAREHOLDER VALUE, REINSTATEMENT OF TRADING AND PROVIDES CORPORATE UPDATE

Newtopia

Photo by <a href="https://unsplash.com/photos/mNGaaLeWEp0">Emma Simpson</a> on<a href="https://unsplash.com/s/photos/health?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText"> Unsplash</a>

&nbsp;

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

There&rsquo;s an old saying that goes, &ldquo;An ounce of prevention is worth a pound of cure,&rdquo; meaning it&rsquo;s easier to prevent something from happening in the first place than to try and fix it after the fact. That holds true for many things in life and is advice that can arguably be applied directly to one&rsquo;s own health and the health of businesses as well.&nbsp;

While this doesn&rsquo;t mean that every illness or ailment can be prevented, steps can be taken to change an individual&#39;s habits and give the human body and mind the best possible chance to stave off the progression of chronic conditions or even prevent their occurrence in the first place.

Knowing the proper steps to prevent, slow, and reverse chronic disease can overwhelm even the most health-conscious individuals. For that, a knowledgeable guide and toolkit of resources are invaluable to anyone willing to bring positive change to their lives. One of those resources is <a href="https://www.newtopia.com/">Newtopia</a> (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NEWUF#OTCQB">NEWUF</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/NEWU#TSXV">NEWU</a>), a tech-enabled habit change provider.

<h2>The Whole Person Approach</h2>

Newtopia is unlike any other telehealth or habit change tool available on the market today. The company&rsquo;s one-size-fits-one whole-person approach focuses on the individual at risk, building that person&rsquo;s confidence, physical and mental wellbeing over time to develop long-term habit change. Newtopia&rsquo;s proven capabilities are evidence-based and grounded in science and have received full recognition from the Centers for Disease Control and Prevention.

Newtopia leverages the best of human &ndash; its health coaches or Inspirators &ndash; with the best of digital &ndash; its proprietary HIPAA-compliant technology platform and data analytics &ndash; to incrementally change habits around nutrition, exercise, and mental wellbeing. By leveraging the genetic profile of the individual, coupled with their social habits and behavioral insights, Newtopia develops a personalized prevention program for each participant that combines virtual care, digital tools, connected devices (wearables, digital scales), and actionable data science.&nbsp;

Newtopia&rsquo;s clients represent a substantial addressable market including self-insured employers (~140 million people), private insurers (~100 million people), and public health / government healthcare providers (~138 million people). The company&rsquo;s client portfolio includes very well-known brands such as CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), and Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>), who believe investing in their workers is essential to the long-term financial success of their companies.

Although Newtopia&rsquo;s focus has been on type 2 diabetes, heart disease, stroke, and obesity, the changes in habits that are suggested through the program can also have a positive impact on a person&rsquo;s mental health, soothe other chronic conditions, and improve overall resilience. This innovative whole-person approach &ndash; the concept that physical and mental wellbeing are linked &ndash; has arguably become even more important as a result of COVID-19.

<h2>How it Works</h2>

It all begins with meeting individuals at a point of concern with their health during the onboarding process. Using biometric testing and online health assessment tools, Newtopia identifies the risk eligibility of individuals. Candidates are then matched with an Inspirator and the right smart technology which together walks them through the recommended steps towards habit change - whether that be new exercise routines, dietary changes, or methods to improve and enhance mental health. Through virtual coaching sessions, simple tracking, gaming, and a curated social health community, participants work to meet incremental goals to change everyday habits and improve their overall health. By forming deep and lasting participant relationships, Newtopia is also able to offer curation of other available health benefits and deliver greater adherence to its program.

The ultimate goal is to lead each individual to a healthier place which could mean fewer trips to the doctor or emergency room, reduced reliance on medication, and more opportunities to enjoy life. Newtopia&rsquo;s platform not only improves health but also saves money for health insurers through reduced health insurance costs. For instance, a healthy individual incurs&nbsp;~$3,400 a year in medical expenses. With one or two risk factors such as elevated weight, blood pressure, or glucose, those expenses increase to $5,400 a year. Once someone reaches the chronic category, medical costs can be upwards of $15,000 to $20,000 or more. That is a massive unmanaged liability for health insurers.

<h2>A Win-Win Business Opportunity</h2>

Today 90% of America&rsquo;s $4.0 trillion of annual healthcare costs paid for by health insurers are attributed to individuals with chronic and mental health conditions. But, what if we could reduce this figure? Newtopia does just that by limiting healthcare costs for individuals, employers, and insurance providers. The cost savings positively impact all three groups. With the world still facing a massive pandemic, healthcare costs continue to skyrocket and the time to find ways to reduce such costs is now.&nbsp;&nbsp;

Newtopia&rsquo;s cost savings and return on investment to health insurers, including self-insured employers, private and government health plans, have been proven time and time again. In a randomized controlled trial conducted in conjunction with Aetna, Newtopia&rsquo;s program showed a yearly cost savings of just under $1,500 per employee. In another study conducted with Medicare Advantage participants, cost savings totaled $1,700 per individual per year. These findings demonstrate that if a company chooses to partner with Newtopia for its workforce as a benefit, it may be likely to result in a healthier employee or member population and drive significant savings.

Are you curious about how much <a href="https://investor.newtopia.com/overview/default.aspx">a company could save</a> by providing its employees the opportunity to improve their physical and mental health and decrease chronic disease occurrences? Use <a href="https://www.newtopia.com/b2b/">this calculator</a> to find out.

<h2>The Bigger Picture</h2>

As we continue to weather the global pandemic, we are seeing a considerable surge in the number of chronic disease cases, leaving health insurers and the insured to pick up the pieces. Newtopia is aiming to turn the healthcare industry on its side, to stop monetizing sickness and instead invest in long-term habit change.&nbsp; When people change their habits, they can change their lives and the lives of those around them. Coming together and taking a proactive approach to individuals&rsquo; health can have long-lasting benefits for all individuals and health insurers.&nbsp;

<h2>Opportunity to Learn More</h2>

Interested in learning more about Newtopia? Founder and CEO Jeff Ruby will be presenting next week at Benzinga&rsquo;s Healthcare Conference at 3:20 PM ET on Thursday, September 30th. Mr. Ruby will also be available to host investor meetings throughout the day. You can learn more about the event <a href="https://www.benzinga.com/events/small-cap/healthcare/">here</a>.&nbsp;

&nbsp;

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Newtopia

News

Latest news for Newtopia (OTC:NEWUF) Stock

Thursday, September 23, 2021